University of Kentucky

UKnowledge
Microbiology, Immunology, and Molecular
Genetics Faculty Publications

Microbiology, Immunology, and Molecular
Genetics

2-19-2014

B Cell Tolerance in Health and Disease
Murali Gururajan
Cedars-Sinai Medical Center

Vishal J. Sindhava
University of Pennsylvania

Subbarao Bondada
University of Kentucky, bondada@uky.edu

Follow this and additional works at: https://uknowledge.uky.edu/microbio_facpub
Part of the Medical Immunology Commons, Medical Microbiology Commons, and the Molecular
Genetics Commons

Right click to open a feedback form in a new tab to let us know how this document benefits you.
Repository Citation
Gururajan, Murali; Sindhava, Vishal J.; and Bondada, Subbarao, "B Cell Tolerance in Health and Disease"
(2014). Microbiology, Immunology, and Molecular Genetics Faculty Publications. 92.
https://uknowledge.uky.edu/microbio_facpub/92

This Review is brought to you for free and open access by the Microbiology, Immunology, and Molecular Genetics
at UKnowledge. It has been accepted for inclusion in Microbiology, Immunology, and Molecular Genetics Faculty
Publications by an authorized administrator of UKnowledge. For more information, please contact
UKnowledge@lsv.uky.edu.

B Cell Tolerance in Health and Disease
Digital Object Identifier (DOI)
https://doi.org/10.3390/antib3010116

Notes/Citation Information
Published in Antibodies, v. 3, issue 1, p. 116-129.
© 2014 by the authors; licensee MDPI, Basel, Switzerland.
This article is an open access article distributed under the terms and conditions of the Creative
Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).

This review is available at UKnowledge: https://uknowledge.uky.edu/microbio_facpub/92

Antibodies 2014, 3, 116-129; doi:10.3390/antib3010116
OPEN ACCESS

antibodies
ISSN 2073-4468
www.mdpi.com/journal/antibodies
Review

B Cell Tolerance in Health and Disease
Murali Gururajan 1, Vishal J. Sindhava 2 and Subbarao Bondada 3,*
1

2

3

Division of Hematology and Oncology, Department of Medicine, Cedars-Sinai Medical Center,
Los Angeles, CA 90048, USA, E-Mail: Murali.Gururajan@cshs.org
Department of Pathology and Laboratory Medicine, University of Pennsylvania School of
Medicine, Philadelphia, PA 19104, USA; E-Mail: Sindhava@mail.med.upenn.edu
Department of Microbiology, Immunology and Molecular Genetics and Markey Cancer Research
Center, University of Kentucky, Lexington, KY 40536, USA

* Author to whom correspondence should be addressed; E-Mail: Bondada@email.uky.edu
Fax: 859-257-9608.
Received: 21 November 2013; in revised form: 11 February 2014 / Accepted: 13 February 2014 /
Published: 19 February 2014

Abstract: B lymphocyte receptors are generated randomly during the bone marrow
developmental phase of B cells. Hence, the B cell repertoire consists of both self and
foreign antigen specificities necessitating specific tolerance mechanisms to eliminate selfreactive B cells. This review summarizes the major mechanisms of B cell tolerance, which
include clonal deletion, anergy and receptor editing. In the bone marrow presentation of
antigen in membrane bound form is more effective than soluble form and the role of
dendritic cells in this process is discussed. Toll like receptor derived signals affect
activation of B cells by certain ligands such as nucleic acids and have been shown to play
crucial roles in the development of autoimmunity in several animal models. In the
periphery availability of BAFF, a B cell survival factor plays a critical role in the survival
of self-reactive B cells. Antibodies against BAFF have been found to be effective
therapeutic agents in lupus like autoimmune diseases. Recent developments are targeting
anergy to control the growth of chronic lymphocytic leukemia cells.
Keywords: B cells; tolerance; Toll-like receptors; B-1 B cells; autoimmunity
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1. Introduction
The development of an adaptive immune system requires generation of antibody receptors with
varied affinities some of which will have reactivity to self-antigens. In the B-cell lineage, self-reactive
B cells are eliminated in the bone marrow (Central tolerance) and the spleen (Peripheral tolerance). By
utilizing a variety of transgenic mouse models, researchers have demonstrated that the central
tolerance mechanisms exclude autoreactive immature B cells and prevent cells that exhibit selfreactive B-cell receptors from entry into the peripheral B-cell compartment. Additional studies have
revealed mechanisms that promote the differentiation of non-autoreactive immature B cells and their
positive selection into the peripheral B-cell compartment. These central tolerance mechanisms are
fundamental to the generation of a naive B-cell repertoire that is largely devoid of self-reactivity while
capable of reacting with any foreign antigen.
B-cells are generated in the bone marrow in a tightly regulated manner. Productive rearrangement
of immunoglobulin heavy (IgH) and light (IgL) chain gene segments results in the generation and
expression of the mature B-cell antigen receptor (BCR) at the cell surface. While specific combination
of Ig H and L chains determines the antigenic specificity of the newly formed BCR, its association
with Ig-α and Ig-β allows transduction of a signal inside the cell that directs cell fate [1,2]. Developing
B cells first express a mature BCR on the cell surface in the form of IgM and as such are classified as
immature B cells (Figure 1) [3–5]. It is at the immature B-cell stage that the BCR is exposed to
autoantigens in the bone marrow. Central B-cell tolerance is the process that negatively selects newly
generated immature B cells that react with a self-antigen in the bone marrow environment. This is
considered the first checkpoint of B-cell tolerance, and the outcome of this checkpoint mechanism is
fundamental to the generation of a naive B cell repertoire that contains BCRs reactive to foreign
antigens and is mostly devoid of self-reactive specificities. Once the central checkpoint is successfully
overcome, immature B cells differentiate into transitional and mature B cells in the spleen [4,6,7].
However, a fraction of autoreactive immature B cells, that retains low reactivity to self-antigens,
escapes the central checkpoint of tolerance and migrates into the periphery [6–8].
2. Central Tolerance: Clonal Deletion, Anergy and Receptor Editing
Burnet’s clonal selection theory suggested that lymphocyte clones that react to self are eliminated to
prevent immune responses against self-antigens [9]. Seminal work from many investigators involved
injecting antibodies reactive toward immunoglobulin (Ig) chains into newborn mice and rabbits to test
whether newly generated B cells reacted with a “self-antigen,” (in this case, the rabbit anti-Ig antibody
acts like a self-antigen), would either be deleted or modulated [10–17]. Consistent with such a
hypothesis, injection of anti-Ig antibody and anti-idiotypic antibodies in newborn animals resulted in
the elimination of Ig and idiotype-expressing B cells, respectively. Later on, with the advancement of
transgenic mice technology, anti-hen egg lysozyme (HEL) and anti-H-2Kk (and H-2Kb) Ig transgenic
mice were developed with the purpose of testing whether newly generated autoreactive B cells were
either eliminated or suppressed on recognition of their specific self-antigen. These studies indicated
that when an immature B cell reacts with a self-antigen with high avidity, such as a highly expressed
membrane-bound protein, it undergoes apoptosis within 2–3 d [3,18]. In contrast, low avidity
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interactions of B cells with self-antigens induce unresponsiveness to subsequent stimulation or anergy
but allowed for migration into peripheral compartment. The anergic B cells fail to enter follicle and
have reduced life-span [3]. Therefore, it was concluded that clonal deletion and anergy were major
mechanisms mediating central tolerance of developing autoreactive B cells, resulting in the elimination
of autoreactive clones, and preventing immune responses against self. However, later studies showed
that clonal deletion and anergy are not the only modes of selection against autoreactive immature B
cells, but there operates another system, namely, receptor editing. Several important studies that
utilized immunoglobulin heavy and/or light chain transgenic mouse models in which the self-antigens
were either MHC class I or DNA showed that autoreactive immature B cells “edit” their antigen
receptors [19,20]. Specifically, autoreactive immature B cells reactivated their Ig gene rearrangement
program at the Ig light chain loci resulting in the expression of a new light chain that paired with the
existing H chain to form a non-autoreactive BCR, an event that promoted the selection of these edited
B cells into the periphery. The concept of “receptor editing” was thus born. Several studies with
human B cells have shown that receptor editing also plays a role in shaping human B cell repertoire
and failures in regulation of these mechanisms are involved in lupus like autoimmune diseases [21].
Despite a critical role for BCR affinity in deciding the fate of immature B cells, their selection is also
influenced by the bone marrow microenvironment [2].
3. Peripheral Tolerance – Role of BAFF (BLyS)
The central tolerance mechanisms eliminate approximately 90% of the self-reactive B cell
pool [5,22]. Despite the presence of clonal deletion, anergy and receptor editing mechanisms, several
autoreactive clones bypass these checkpoints and are found in peripheral B cell pool [8,23,24].
Immature B cells that survived the central tolerance leave the bone marrow and continue their
development as transitional B cells in the periphery. Here they undergo peripheral tolerance based on
their BCR specificity and signal strength. The BCR signal strength must fall within the range for
further maturation and selection: above the “tonic” signaling for positive selection and below the
threshold signaling for negative selection [2,25,26]. The “transitional B cell tolerance” is the first B cell
tolerance check point in the periphery, which eliminates about two-thirds of the transitional B cells [5].
Unlike the central tolerance mechanisms, the stringency of transitional B-cell tolerance is plastic and
selection depends on the interplay between BCR-mediated signals and a B cell survival factor, called B
lymphocyte stimulator (BAFF, also known as BLyS) signaling [27].
BAFF is a soluble type II transmembrane protein that promotes key biological functions including
peripheral B-cell survival and homeostasis [28]. In addition to promoting B-cell survival, BAFF also
regulates expression of CD21/35 on the surface of B cells [27,29]. BAFF deficiency results in a
reduction in the number of peripheral B cells and a diminished capacity to mount robust humoral
immune responses. Overexpression of BAFF has been linked to human autoimmunity, and recent data
provide clues as to how excessive secretion of BAFF may allow the emergence of autoreactive B cells
in mice and humans [28,29]. BAFF binds to three receptors: BAFF receptor 3 (BR3; also known as
BAFF-R), transmembrane activator-1 and calcium modulator and cyclophilin ligand-interactor
(TACI), and B cell maturation antigen (BCMA). BAFF-R is one of the BAFF receptors expressed on
all peripheral blood B cells in both mice and humans. In the mouse spleen, BAFF-R is most highly
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expressed on transitional type 2 (T2) B cells, followed by mature and marginal zone (MZ) B cells,
while T1 cells having lower levels of BAFF-R on the surface, and GC B cells have reduced expression
compared to mature follicular B cells. Human tonsillar B cells have a high level of BAFF-R
expression, and like mouse, tonsillar B cells with a GC phenotype express BAFF-R in reduced
levels [30–32]. It was shown that BAFF-R is not expressed on B-cell precursors in the bone marrow.
BAFF-R was initially believed to be expressed exclusively by B cells; however, BAFF-R was recently
found to be expressed on a subset of mouse splenic T cells and on human anti-CD3-activated
peripheral blood T cells [33–36]. Close examination of tonsillar T cells revealed that a large proportion
of effector and memory T cells express BAFF-R, while naive T cells are negative [31,32]. Although
mRNA for BCMA, another receptor for BAFF can be found in the spleen, lymph nodes, and several
B-lineage cell lines, cell-surface BCMA is undetectable. TACI, a third receptor for BAFF was found to
be expressed on B cells and a subset of activated T cells [31,32]. In the mouse, splenic MZ and T2 B
cells have the highest level of TACI expression, while expression on T1 and mature B cells is low or
absent. In the absence of BAFF, B cell development remains normal in the bone marrow, but
peripheral B cells are reduced significantly. BAFF signaling is crucial for the survival of late
transitional (T2 and T3), follicular and marginal zone B cells, whereas B-1 B cells remain unaffected
due to lack of BAFF [37,38].
Elevated levels of BAFF lead to defect in transitional B cell tolerance and a breach in the peripheral
tolerance. Studies with the immunoglobulin knock-in mice that express self-reactive BCRs show that
most of the transitional B cells are negatively selected during transitional B cell tolerance. However,
administration of exogenous BAFF in these mice results in an increase in number of self-reactive B
cells in the mature B cell pool [39,40]. Thus, B cells that would normally be deleted through negative
selection instead survive because of BAFF signaling and join the mature naïve B-cell pool. These
studies suggest that BAFF is a limiting factor in transitional B-cell tolerance. Increased levels of BAFF
lowered the BCR affinity threshold required for positive selection with a consequence that
self-reactive B cells with a low affinity BCR were rescued into the peripheral repertoire. Consistent
with this idea, aberrant transitional tolerance processes because of elevated levels of BAFF have been
identified in patients with antibody mediated autoimmune diseases [41–44]. These observations made
BAFF an attractive therapeutic target, and subsequently a BAFF-blocking monoclonal antibody,
Belimumab (Benlysta), received FDA approval in 2011 as a treatment for patients with systemic lupus
erythematosus (SLE) [45,46]. Treatment with Belimumab leads to a significant reduction in autoantibodies
and selected B cell subsets (naïve, transitional but not memory B cells) in SLE patients [47]. Though
Belimumab has promising potential, it does have reduced benefits in long term clinical care of
patients. Clinical trials comparing two doses of Belimumab (1 or 10 mg/kg), were performed in adult
patients (n = 1684). It was shown that after 52 weeks patients who responded to the drug were about
10% higher with belimumab (10 mg/kg) than with placebo. However, this response was not observed
in one of the trials at 76 weeks [48]. Although it was demonstrated that treating patients with
Belimumab provided no statistically significant therapeutic benefit, the positive outcome of these two
trials is that patients with highly active disease had clinical benefit. Belimumab has been shown to be
immunosuppressive and to exacerbate the effects when combined with other immunosuppressive
drugs [48–50]. Different mechanisms of B cell tolerance in bone marrow and periphery are
summarized in Figure 1.
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Figure 1. Mechanisms of B-cell tolerance in bone marrow and periphery: Both clonal
deletion and anergy are mechanisms utilized in the primary as well as peripheral lymphoid
organs. Strength of BCR signaling affects the fate of the B cells undergoing tolerance.
Receptor editing occurs primarily in the bone marrow. Transitional B cells are found in the
bone marrow and spleen. Peripheral tolerance is primarily found in splenic transitional B
cells, which depends on tonic BCR signaling thresholds and survival signals from BAFF.

4. Peripheral Tolerance - Role of Toll-Like Receptors
Toll-like receptors (TLRs) are pattern recognition receptors that recognize pathogen associated
molecular patterns (PAMPs) [51,52]. TLR-mediated recognition of PAMPS leads to activation of
innate immune cells [53]. TLR signaling promotes activation and maturation of innate immune cells,
which instructs and supports T-cell activation, leading to cell-mediated adaptive immune response.
Activated antigen-specific T cells and naïve B cells interact with each other (cognate interaction),
which leads to B-cell clonal expansion and differentiation and antibody secretion. Recent evidence
suggests that in addition to TLR signaling in cells of the innate immune system, direct TLR mediated
activation of B cells is also required for eliciting humoral immune response. However, multiple B cell
subsets exists that play distinct roles during humoral immune responses. For example, follicular B cells
are shown to be important for T-dependent immune responses whereas marginal zone B cells are
important for T-independent immune responses. Marginal zone B cells are shown to be in a preactivated state and respond rapidly to LPS and secrete antibody in vitro. Peyer’s patch B cells in the
intestine play critical role in mucosal immune response by secreting IgA that binds to pathogens and
prevents enteric infections. B-1 B cells, a subset of B cells in the peritoneal cavity is the source of
natural IgM present in the serum and plays an important role in immunity against blood borne
pathogens [6,54]. It was shown that B-cell subsets express all known TLRs except 5 and 8 [55].
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In a series of landmark studies, it was demonstrated that TLRs expressed by B cells can also
recognize self-antigens released from host tissues that are damaged, and such self-recognition by the B
cell intrinsic TLR can potentially promote the development of autoimmune disease by breaking B-cell
tolerance. Studies from transgenic mice reveal that immune complexes (ICs) consisting of IgG bound
to mammalian DNA have been shown to effectively activate transgenic rheumatoid factor (RF)
specific B cells through a process that involves BCR recognition of the IC and subsequent delivery of
the DNA to TLR9 sequestered in an endosomal/lysosomal compartment [56–58]. These low affinity
RF specific B cells do not proliferate in response to protein-containing ICs. The chromatin ICs, but not
protein ICs, stimulate myeloid and plasmacytoid DCs to secrete cytokines, through coengagement of
both FcγRs and TLR9. Under specific conditions, mammalian DNA can also directly stimulate DNAreactive cells, through a TLR9-dependent process. However, the role of TLR9 in lupus appears more
complex since deletion of Tlr9 gene in some mouse models protects against autoimmunity [59].
In addition to the DNA and DNA containing ICs, RNA and RNA binding proteins, such as
Sm/RNP, constitute a second major category of autoantigens frequently targeted in systemic
autoimmune diseases such as systemic lupus erythematosus (SLE). Sm/RNP particles consist of the U1
RNA bound by Sm and other associated proteins. Recent studies suggest that TLR7 and TLR8 act as
receptors for single stranded RNA expressed by the viruses. In this context, the ssRNA was found to
be a particularly effective ligand for TLR7 and TLR8 [56,60]. These observations raised the possibility
that the interactions between BCR and TLRs that lead to DNA dependent activation of autoreactive B
cells and DCs, would also apply to TLR7/8 involvement in the activation of B cells by RNAassociated autoantigens [59]. In agreement with such a concept, TLR7 deficiency ameliorated
autoimmunity in murine models [59]. Thus, these observations in mouse models are consistent with
the fact that autoantibodies reactive with DNA or DNA-associated proteins are the earliest and most
commonly prevalent serological markers of human SLE [47,57].
5. Role of Dendritic Cells in Central and Peripheral Tolerance
Interaction of dendritic cells (DCs) with B cells and T cells plays an important role in the regulation
of immune responses. DCs express a variety of TLRs and respond to TLR stimuli. DCs were found to
present antigen to both T cells and B cells in a tolerogenic form [61,62]. Immature DCs have been
shown to inhibit and tolerize T cells in vivo because of the absence of a costimulatory signal, whereas
maturation of DCs by TLR or CD40 overcomes this inhibitory effect on T cells [62,63]. Recent studies
suggest that immature bone marrow DCs (iBMDCs) or bone marrow resident DCs, but not mature
bone marrow DCs or Splenic resident DCs [64], strongly inhibited B cell proliferation and
differentiation responses induced by TLR ligation. iBMDCs specifically inhibited TLR2, TLR3, and
TLR4, as well as BCR-induced proliferation, but did not inhibit anti-CD40 or PMA-ionomycininduced B cell proliferation [54,65]. Cell-cycle analysis revealed that iBMDCs block B cell
proliferation by inducing G1-S growth arrest [54]. Similar to the DC-mediated regulation of T cell
responses, maturation of immature BMDCs with TLR ligands overcame the inhibitory effect of DCs
on B cells. Many different TLR ligands can mature DCs in either a MyD88-dependent or MyD88independent manner [66]. Maturation of immature BMDCs via the MyD88-dependent pathway (LPS,

Antibodies 2014, 3

122

peptidoglycan) or the MyD88-independent pathway [poly(I:C)] had similar effects in overcoming the
inhibitory effect of iBMDCs on B cells.
CD22 expression by B cells is critical for the immature BMDC-mediated inhibition of TLR-induced
B cell proliferation [54]. Interestingly, it has been shown that maturation of BMDCs decreases the
expression of sialic acid ligands [67], which is consistent with the role of CD22 in DC–B cell
interaction. It is also possible that the sialic acid binding proteins such as Siglec G, which have been
shown to be important for B-1 cell responses and for Ag-induced tolerance in B cells could play a role
in this process [68]. Unstimulated splenic resident DCs were immature as evident by low CD86 and
class II expression on the surface, compared with LPS mature Spl-RDCs but they did not inhibit
TLR-induced B cell responses. In contrast, bone marrow resident DCs strongly inhibited TLR induced
proliferation of B cells from both the bone marrow and the spleen. Although immature BMDCs
normally are a heterogeneous population of DCs, flow cytometric sorting established that myeloid DCs
in this population have potent inhibitory effects on B cells [64]. It is of interest to note that
Kilmon et al. [69] found that myeloid DCs and macrophages, but not plasmacytoid DCs, inhibited
autoantibody production by self-reactive B cells, but not Ab production by normal B cells.
In thymus, DCs present self-antigen in the context of their MHC and play a role in the negative
selection of T cells. Thus, the DCs in the bone marrow might play a similar role in B cell negative
selection by presenting soluble self-antigens to B cells in membrane bound form in the context of
CD22/SIGLEC-mediated inhibitory signals. In this context, recently it has been shown that ligation of
T-independent Ags with sialic acid epitopes induced B-cell tolerance through their ability to crosslink
SIGLEC family proteins [70,71]. It was proposed that self-antigens that behave like T independent
Ags may use this pathway for self-tolerance. In support of such an idea, mice doubly deficient for
CD22 and Siglec G developed autoantibodies and a moderate form of immune complex mediated
glomerular nephritis [71]. Although the significance of inhibition of TLR responses of bone marrow B
cells is currently unclear, it must be noted that several endogenous TLR ligands have been identified
and have been implicated in the breakdown of self-tolerance in several autoimmune models [72,73].
Some of the endogenous TLR ligands such as high mobility group box 1 and heat shock proteins have
their origin in cell death [74], which is known to occur extensively during B cell development. Defects in
clearance of dead cells have a critical role in the development of autoimmune diseases such as lupus [75].
In the periphery, DCs in mucosal areas and epidermal Langerhans cells (sites of extensive cell
turnover) have anti-inflammatory properties.
6. Human B Cell Tolerance and Its Impact on Human Autoimmune Diseases
In the previous sections, we discussed immunological tolerance in B cells based on studies
performed with transgenic mouse models of B cell tolerance and knockout mice that develop
autoimmune diseases. In humans, most developing autoreactive B cells in healthy individuals are
removed at two distinct steps. A vast majority of B cell clones expressing self-reactive B cell receptors
are eliminated by the central tolerance mechanisms in the bone marrow. A peripheral B cell tolerance
checkpoint further eliminates autoreactive new emigrant B cells before they enter the mature naive B
cell compartment. In patients with active autoimmune diseases including rheumatoid arthritis (RA) or
type 1diabetes (T1D), both the central and peripheral checkpoints are defective [76,77].
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In autoimmune diseases like multiple sclerosis (MS), RA and to a lesser extent T1D, anti-CD20
therapy that depletes B cells has shown some efficacy in ameliorating the disease suggesting that the
deletion of autoreactive B cell clones may reduce disease symptoms in these autoimmune diseases [78].
It was reported that a defective peripheral B cell tolerance checkpoint is observed in all three
autoimmune diseases including MS, T1D, and RA, whereas central B cell tolerance is only impaired in
two out of three autoimmune diseases (T1D and RA but not in MS) [79]. Hence, defects in the deletion
of autoreactive B cell clones in the bone marrow seem to be critical for the development of RA and
T1D, but are dispensable for MS. Genome-wide association studies (GWAS) have demonstrated that
several susceptibility alleles are shared among many different autoimmune diseases [77]. For example,
it has been shown that C1858T polymorphism in the PTPN22 gene is associated with high risk T1D
and RA, but not MS [80]. This PTPN22 mutant blocks both T cell receptor (TCR) and B cell receptor
(BCR) signaling that regulates central tolerance. Consistent with this hypothesis, it was shown that
healthy donors carrying the PTPN22 risk allele lack the ability to eliminate autoreactive B cells in the
bone marrow. This finding is similar to that observed in T1D and RA patients, revealing that this
susceptibility allele is sufficient to confer the impaired central B cell tolerance associated with these
autoimmune diseases. Other susceptibility genes associated with T1D and RA, include BLK, LYN,
PTPN2, and BANK1, all of which affect BCR signaling pathways and may interfere with the removal
of emerging autoreactive B cells [81]. In contrast, none of these polymorphisms, including the
PTPN22 variant, are associated with MS, further demonstrating that alterations in B cell intrinsic
pathways controlling central B cell tolerance may not be necessary for the development of all
autoimmune diseases. It has been demonstrated that disease-associated polymorphisms in MS mainly
affect T helper differentiation and B cell-T cell interactions and not B cell intrinsic pathways [79]. In
contrast to central tolerance mechanisms, the maintenance of the peripheral B cell tolerance checkpoint
is specifically defective in MS patients, which is postulated to be due to defects in regulatory T cell
function [79].
7. Targeting B Cell Anergy for Therapy
Several studies demonstrate that the constitutive B-cell receptor (BCR) signaling and response have
a critical role in the survival and expansion of both B cell lymphoma and the chronic lymphocytic
leukemia (CLL) clones. CLL patients represent a heterogeneous group with one subset exhibiting an
indolent disease whereas others progress rapidly necessitating early therapy. It was observed that
patients with indolent form of CLL are characterized by an expansion of clonal B cells with anergic
features. In this subset of patients, B cells fail to respond to BCR cross-linking as measured by calcium
mobilization and protein tyrosine phosphorylation [82,83]. This was characterized as B cell anergy and
was associated with low levels of surface IgM expression, constitutive activation of ERK1/2 and
NFATc1 signaling. Chronic BCR triggering promoted CLL cell survival selectively in p-ERK+ve
subset and treatment with ERK or NF-AT signaling inhibitors specifically induced apoptosis in this
group of patients. The initial phase of reversal of anergy consists of loss of ERK phosphorylation and
NF-AT nuclear translocation and restoration of B cell unresponsiveness, reinforcing the notion that the
anergic signaling favors the chronic survival of leukemic lymphocytes. Thus, it appears that the
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constitutive signaling observed in B-cell anergy can be efficiently targeted in CLL for therapeutic
purposes [82].
8. Conclusions
The studies of central B-cell tolerance performed in the last 3 decades in mouse models have given
us an understanding of forces that shape the murine naive B-cell repertoire. Future challenges will be
determining the contributions of different forms of tolerance (clonal deletion, anergy, receptor editing
and BAFF thresholds) to the repertoire of human B cells, and to understanding which of these
mechanisms is primarily affected in autoimmune diseases. Another challenge will be to increase our
knowledge of the bone marrow microenvironment to establish whether a specific niche exists for the
self-antigen presentation to newly generated B cells, and for the processes of negative and positive
selection. In particular, we will need to define the cytokines and chemoattractants that influence
immature B-cell selection and their distribution in the marrow environment. Another major challenge
will be to determine what factors regulate tonic BCR signaling in immature B cells, and particularly
what defines the signaling threshold that separates negative and positive selection.
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